Monoclonal B-Lymphocytosis Diagnosis and Management

Definition and Diagnosis

The presence of <5 × 10⁹/L monoclonal B lymphocytes in peripheral blood, without lymphadenopathy, organomegaly, cytopenias, or disease-related symptoms, defines Monoclonal B-Lymphocytosis (MBL) rather than Chronic Lymphocytic Leukemia (CLL) 1, 2, 3, 4
The International Workshop on Chronic Lymphocytic Leukemia recommends that MBL be diagnosed based on the presence of monoclonal B lymphocytes in peripheral blood, with a characteristic immunophenotype (CD5+, CD19+, CD20+, CD23+, with light chain restriction) 1, 2, 4
The European Society for Medical Oncology suggests that the diagnosis of MBL should be considered in patients with a small clonal B-cell population detected by flow cytometry, with a characteristic immunophenotype (CD5+, CD19+, CD20+, CD23+, with light chain restriction) 1, 4

MBL can be detected in up to 5% of subjects with normal blood counts, with frequency increasing with age 1, 4
Progression to frank CLL occurs at a rate of 1-2% per year, meaning the vast majority of MBL cases remain stable indefinitely 1, 2, 3, 4
The American Society of Hematology recommends that patients with MBL should be monitored with periodic clinical assessment and complete blood counts, but no treatment is indicated 1, 4

Mantle cell lymphoma (MCL) must be excluded in CD5+ cases, as it typically does not express CD23 (unlike CLL/MBL which is CD23+) 1, 4
The International Society for Laboratory Hematology recommends that MCL be distinguished from CLL/MBL by checking for cyclin D1 overexpression by RT-PCR or t(11;14) by FISH, and CD200 expression 1, 4

The National Comprehensive Cancer Network recommends that no treatment is indicated for MBL, and observation with periodic clinical assessment and complete blood counts is the appropriate management strategy 1, 4
Routine screening for CLL is not recommended, even in patients with known MBL 1, 4
The European Society for Medical Oncology suggests that bone marrow biopsy is not indicated for MBL unless clinical features suggest progression to CLL (lymphadenopathy, organomegaly, cytopenias) or the immunophenotype is atypical or unclear 1, 4